beta thalassemia

Pharma

Vertex gains FDA expansion of Casgevy to those ages 2 and older

The FDA has granted a label expansion for children ages 2 and up to receive Vertex's gene therapy Casgevy for sickle cell disease or beta thalassemia.

Kevin Dunleavy Jul 6, 2026 11:30am

Vanda, Agios score holiday season FDA approvals

Jan 2, 2026 11:33am

Long-term data shows durability of Vertex's gene therapy Casgevy

Jun 14, 2024 11:12am

Vertex's Casgevy launch progresses as CF drugs post solid growth

May 7, 2024 11:23am

FDA approves Vertex, CRISPR's Casgevy for beta thalassemia

Jan 16, 2024 3:40pm

Agios charts broad path for oral thalassemia med after trial win

Jan 3, 2024 10:49am